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Abstract
Background: This study was conducted to describe the clinical and genetic features of patients with late infantile
metachromatic leukodystrophy.
Methods: Clinical and genetic manifestations of five Taiwanese patients with late infantile metachromatic
leukodystrophy from January 2003 to April 2014 were reviewed. The genetic features of such patients reported in
Asian countries during a period of 20 years were also analyzed.
Results: The median age at disease onset was 1 year and 3 months with the first clinical symptom being gait
disturbance. All five patients became bed-ridden at a median age of 2 years and 5 months. Nerve conduction velocity
revealed demyelinating polyneuropathy and brain MRI disclosed tigroid and leopard skin pattern of dysmyelination in
all 5 patients. All patients had decreased ARSA activities in leukocytes accounting for 15.88 % to 30.75 % of controls.
Five novel mutations, p.A316D, p.G303R, p.Q176X, p.R293X, and c.749 insGCGGGCCA, were identified in our case series.
Eighteen patients, including our 5 patients, were reported in Asian countries. A total of 22 different disease-causing
alleles were found, in which p.W320X was identified in Taiwan and China, and p.G101V was found in Taiwan and Korea.
Conclusions: Patients with late infantile metachromatic leukodystrophy exhibited a rapid and devastating clinical
course. The pattern of dysmyelination on brain MRI together with peripheral demyelination polyneuropathy indicates
that evaluation of ARSA activity in leukocytes is warranted. A wide diversity of ARSA gene mutations was noted in Asia.
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Background
Metachromatic leukodystrophy (MLD) is a rare auto-
somal recessive inherited disease, which is caused by a
deficiency in the enzyme activity of Arylsulfatase A
(ARSA). ARSA is required for the hydrolysis of sulfated
glycosphingolipids, which are also known as sulfatides,
and its deficiency results in excessive accumulation of
sulfatide in myelin in the nervous system, the bile ducts
of the liver, and the distal tubules of the kidney [1–3].
ARSA deficiency results from a mutation in the
ARSA gene, which spans 3.2 kb of genomic DNA on
chromosome 22q13 [2, 4]. Clinically, the differences
in residual enzyme activity of ARSA cause a great di-
versity of onset age of the disease and the severity of
the clinical course. Based on the age of disease onset,
MLD can be divided into three forms: late infantile,
juvenile, and adult MLD [4].
Late infantile MLD is the most common form of
MLD, which accounts for 50–60 % of all cases [5] and
incidence is estimated to range from 1 in 40,000 to 1 in
170,000 newborns [6]. The age of disease onset is usually
between 18 and 24 months with the first recognizable
feature of gait disturbance. Afterwards, rapid deterior-
ation of motor, speech, and intellectual functions
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develop over the following months [7, 8]. Because of the
profound ARSA deficiency and progressive demyelin-
ation, such cases usually manifest a rapid and devastat-
ing neurodegenerative clinical course [1]. Inevitable
neurological sequelae develop as the disease progresses,
such as decorticate postures, impaired feeding and swal-
lowing due to pseudobulbar palsies, seizures, and severe
psychomotor retardation. Those patients eventually ex-
pire within the first decade of life [4]. Currently, feasible
therapeutic options are limited to palliative and support-
ive treatments [1, 2, 9–12].
Here we report the clinical manifestations, neuroimag-
ing studies, ARSA enzyme activity, ARSA gene muta-
tions, and neurological outcomes of five Taiwanese
patients with late infantile MLD. In addition, the differ-
ences in ARSA gene mutations between Taiwan and
other Asian countries are noted.
Methods
Study sample
This was a retrospective, uncontrolled, nonblinded
study in which cases from a period spanning over a
decade were analyzed. Between January 2003 and
April 2014, a total of five patients diagnosed with late
infantile MLD were enrolled. All patients underwent
detailed physical and neurological examinations, and
basic laboratory tests, including complete blood
count, blood sugar, creatine phosphokinase, electro-
lytes, liver function test, renal function test, blood
lactate level, arterial blood gas analysis, and urine
routine, as well as metabolic surveys, including assays
of blood amino acids and urinary organic acids.
Spinal tap was administered to patients with their
parents’ consent, and the values of cerebrospinal fluid
(CSF) and assay of CSF amino acids were determined.
Neurophysiological studies, including electroencephal-
ography (EEG), auditory evoked potential (AEP), and
visual evoked potential (VEP) were performed. Bio-
chemical enzyme activities for lysosomal disorders
were analyzed. Brain magnetic resonance imaging
(MRI) and nerve conduction velocity (NCV) were
performed with their parents’ consent.
The diagnostic criteria of late infantile MLD in our
case series included: 1) disease onset at age younger than
2 years following by a clinically devastating regression of
motor, language, and cognition functions; 2) tigroid and
leopard skin pattern of dysmyelination on the brain
MRI; 3) decreased ARSA activity in leukocytes; and 4)
pathognomonic ARSA gene mutations [4].
Molecular analysis
Genomic DNA was extracted from peripheral blood sam-
ples. All the exons of the ARSA gene were amplified by
polymerase chain reaction (PCR) with their corresponding
intronic primers. PCR products were subjected to bidirec-
tional sequencing using a Big-Dye Terminator v3.1 Cycle
Sequencing Kit and an ABI Prism 3100 genetic
analyzer (Applied Biosystems, Foster City, CA). The
protein sequence was based on GenBank accession
no. NM_00487.5. Written informed consent was ob-
tained from all participants’ parents prior to collec-
tion of blood samples for molecular studies.
Data collection
The medical records of these five patients were
reviewed. Patients’ clinical information, including gender,
age at disease onset, histories of developmental mile-
stones prior to the onset of the disease, duration be-
tween disease onset and psychomotor regression, and
clinical outcomes, were collected. Laboratory data, neu-
roimaging findings, neurophysiological studies, ARSA
enzyme activities, and ARSA gene mutations were ana-
lyzed. This study was approved by the Institutional Re-
view Board (IRB TCVGH No. CF14213).
Literature review
We searched the MEDLINE and PubMed database
using the keywords “metachromatic leukodystrophy”.
We reviewed cases diagnosed with late infantile
MLD and reported in Asian countries from the
period 1995 to 2014. In our study, patients with mo-
lecular analysis of ARSA gene mutations were re-
cruited. In order to make meaningful comparisons
between ARSA gene mutations in Taiwan and those
reported in other Asian countries, the genomic data
of all patients identified in the MEDLINE and
PubMed search were re-interpreted with respect to
the change in protein sequences of ARSA amino
acids based on GenBank accession no. NM_00487.5
if a patient’s sequencing results were originally inter-
preted by GenBank accession no. NM_00487.3 or
GenBank accession no. NM_00487.4.
Results
The clinical features, laboratory data, neurophysio-
logical studies, and neuroimaging findings of the five
late infantile MLD Taiwanese patients, three boys and
two girls, are shown in Table 1.
The median age at disease onset was 1 year and
3 months, with a range from 1 year 2 months to 1 year
and 11 months. All of the patients exhibited the first
recognizable clinical symptoms of gait disturbances with
brisk deep tendon reflexes and increased tonicity over the
bilateral lower legs upon neurological examinations at the
first visit. After the onset of the disease, rapid psycho-
motor regression developed. All patients became bed-
ridden at a median age of 2 years and 5 months,
ranging from 1 year 7 months to 3 years and
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6 months. The times at which language function
regressed to “unable to speak” and social function de-
teriorated to “loss of eye contact” were available in 4
and 3 patients, respectively. The median age of symp-
toms in the aforementioned patients was 2 years and
6 months and 3 years and 5 months, respectively.
Epileptic seizures occurred in patients 3 and 5 at age
3 years and 3 years and 6 months, respectively. Re-
garding the clinical outcomes during the long-term
period of follow-up, patients 2 and 4 died of respira-
tory failure at the ages of 7 years and 4 months and
4 years and 9 months, respectively. Patient 5, aged
8 years, is still alive with significant neurological se-
quelae. Patients 1 and 3 were lost to follow-up.
Three patients received a spinal tap and all of them
showed elevated levels of protein in CSF analysis. The
results of neurophysiological studies revealed that pa-
tients 1 and 4 showed no response with respect to AEPs
Table 1 Clinical manifestations, laboratory data, neurophysiological studies, and neuroimaging findings of five patients with
late-infantile metachromatic leukodystrophy
Patient 1 2 3 4 5
Gender M F F M M
Age at disease onset 1 yr 3mo 1 yr 2mo 1 yr 3mo 1 yr 2mo 1 yr 11mo
Age at first visit 2 yr 4mo 1 yr 11mo 2 yr 1 yr 8mo 2 yr
Neurological examinations at first visit
Muscle tone Hypertonicity Hypertonicity Hypertonicity Hypertonicity Hypertonicity
Deep tendon reflexes Increased Increased Increased Increased Increased
Babinski sign Negative Positive Positive Positive Positive
Ankle clonus Negative Negative Positive Negative Positive
Posturing Spasticity Spasticity Decorticate Spasticity Spasticity
Laboratory data
CSF protein level, mg/dl
(Normal range, 20-45 mg/dl)
Not done 135 200 171.4 Not done
Neurophysiological studies
Electroencephalography
At first visit AS AS AS AS AS
Follow-up Not done AS AS, BS BS, focal spikes BS
Auditory evoked potential No response Normal Normal No response Not done
Visual evoked potential Right side delay Normal Normal Normal Not done
Nerve conduction velocity
Demyelinating polyneuropathy Yes Yes Yes Yes Yes
Neuroimaging findings
Brain MRI
Dysmyelination pattern resembling tiger skin Yes Yes Yes Yes Yes
Spinal MRI
Signal change over the white matter Not done Yes Yes Not done Not done
Psychomotor regression
Bed-ridden status, age 2 yr 5mo 2 yr 2mo 3 yr 4mo 1 yr 7mo 3 yr 6mo
Being unable to speak, age Not available 2 yr 3 yr 1 yr 7mo 3 yr
Loss of eye contact, age Not available Not available 3 yr 5mo 2 yr 9mo 4 yr 4mo
Seizure onset, age Not available Not available 3 yr Never 3 yr 6mo
Neurological follow-up
Gastric tube implantation for feeding, age Not available 2 yr 6mo 3 yr 8mo 2 yr 3 yr 6mo
Home BiPAP for respiratory support, age Not available 5 yr 1mo Nil Nil Nil
Outcome Loss of follow-up Died Loss of follow-up Died Alive
7 yr 4mo 4 yr 9mo 8 yr
AS absence of sleep spindles, BS background slowing, CSF cerebrospinal fluid, F female, M male, mo months, MRI magnetic resonance imaging, yr years
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and patient 1 had a delayed response on the VEP evalu-
ation. EEG at the first visit revealed nonspecific findings
with absence of sleep spindles in all five patients. The
follow-up EEGs were recorded depending on the pa-
tients’ clinical condition: EEGs showed nonspecific find-
ings with background slowing in three patients and focal
spikes in patient 4. NCV and brain MRI were performed in
all five patients. NCVs revealed demyelinating polyneurop-
athy. Cranial MRIs disclosed tigroid and leopard skin pat-
tern of dysmyelination (Fig. 1a-o). Spinal MRIs of patients 2
and 3 showed signal changes over the white matter.
ARSA activity in leukocytes and ARSA gene mutations
in our case series are shown in Table 2. All cases had sig-
nificantly decreased ARSA activities in leukocytes with
levels of 11.29 to 21.86 nmol/per milligram of protein/hr
(normal, > 71 nmol/per milligram of protein/hr), which
accounted for 15.88–30.75 % of controls. For the ARSA
gene mutations, a total of eleven alleles were identified, in-
cluding an additional pseudodeficiency allele of p.N352S
in patient 2 (Fig. 2a-e). There were nine different disease-
causing alleles, including four missense mutations of
p.A316D, p.F249S, p.G101V, and p.G303R, three nonsense
mutations of p.W320X, p.Q176X, and p.R293X, and two
frameshift mutations of c.1344_1345 dupC and c.749
insGCGGGCCA. Five alleles, p.A316D, p.G303R,
p.Q176X, p.R293X, and c.749 insGCGGGCCA, were
novel mutations. All our reported cases were heterozygous
gene mutations.
As shown in Table 2, 13 patients with late infantile
MLD in Asian countries were reported in the period
1995–2014 [13–19], including seven from India, three
from Japan, two from China, and one from Korea. Based
on GenBank accession no. NM_00487.5 for changes in
protein sequences of ARSA amino acids, a wide diversity
of ARSA gene mutations were found. Excluding 3 cases
in India for whom 3 alleles were not found, 15 different
alleles in 23 alleles were identified. Six of 13 patients car-
ried heterozygous gene mutations and seven were homo-
zygous ARSA gene mutations. Taken together, there was
a total of 18 patients, including our 5 patients, diagnosed
with late infantile MLD with ARSA gene mutations in
Asia, and 22 different alleles were identified. p.W320X
was found in Taiwan and China, and p.G101V in Taiwan
and Korea. Both p.W320X and p.G101Vwere found in
three of the 33 alleles, with allele frequency of 9 %.
Discussion
The clinical course of patients with late infantile MLD
typically involves initial presentation of unsteady gait at
the age of 1 year and 6 months, according to reports in
the literature. Around the age of 3 years, they no longer
have any locomotion activity and head or trunk control
is absent, ultimately leading to bed-ridden status [7, 20].
In addition to motor function regression, they also
experience the first language difficulties at a median age
of about 2.5 years, and loss of verbal communication oc-
curs at about 2 to 2.5 years after the onset of the disease
[8]. Overall, our case series also observed a similar clin-
ical course to those reported in the literature report. The
median durations between disease onset and motor
function regression to bed-ridden status and no verbal
communication were 1 year and 2 months, and
11.5 months, respectively. Regarding the clinical out-
comes, there are no reliable treatment options for pa-
tients with late infantile MLD [1, 9–12]. With supportive
treatment, including gastric tube placement for feeding
and antibiotic coverage during infection, patients could
survive in a vegetative state for years [20], but they often
die of aspiration pneumonia or bronchopneumonia within
the first decade of life [4]. Patients 2 and 4 in our series
died of respiratory failure 6 years and 2 months and 3 years
and seven months, respectively, after disease onset.
In patients with late infantile MLD, T2-weighted brain
MRI usually showed symmetric high signal intensity ini-
tially in the parietal-occipital central white matter,
followed by frontal central white matter changes, which
then spread to the commissural fibers of the corpus cal-
losum and the periventricular white matter with a
homogeneous change of pattern parallel to the course of
the disease [21–24]. In addition to central nervous sys-
tem (CNS) involvement, peripheral neuropathy was also
evident in these patients, which was associated with uni-
form slowing of both motor and sensory NCVs and risk
of developing unsteady gait and ataxia [25–28]. All of
our 5 patients had characteristic tigroid and leopard skin
pattern of dysmyelination on brain MRI [29] and demye-
lination polyneuropathy on NCV. If there appears to be
involvement in both the CNS and peripheral nerve sys-
tem in patients with suspected late infantile MLD, this
could provide a valuable diagnostic clue for clinical
pediatric neurologists to proceed to the next step and
evaluate ARSA activity in leukocytes [30].
A pathogenic factor of late infantile MLD is absence
or dramatic loss of ARSA activity, which usually ac-
counts for less than 15 % of controls [31]. Our case
series showed the reduction in ARSA activity ranged
from 15.88–30.75 % compared with controls. However,
low ARSA level was not sufficient to make a definitive
diagnosis of MLD. In healthy individuals, some people
have ARSA activity as low as 15–50 % of controls. This
condition is called ARSA pseudodeficiency, which is a
polymorphism [31]. Although a slight deficiency in
ARSA activity, with levels 50–70 % that of controls,
might be associated with pervasive developmental disor-
ders, ARSA pseudodeficiency does not lead to neuro-
logical impairments [31]. In the general population, the
frequency of ARSA pseudodeficiency alleles is about 7–
15 %. Therefore, an accurate diagnosis of late infantile






Fig. 1 (See legend on next page.)
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MLD is based on a combination of clinical features,
biochemical analysis of low residual enzyme activity
of ARSA in leukocytes, together with pathognomonic
ARSA gene mutations [32]. Regarding the correlation
between ARSA activity and age of disease onset, we
observed that our patients 1 to 4 had lower ARSA ac-
tivities, ranged from 11.29 to 15.23 nmol/mg Protein/
hr, whose disease onset were between 1 year 2 months
old and 1 year 3 months old. Patient 5 had ARSA ac-
tivity of 21.86 nmol/mg Protein/hr, and his disease
onset was 1 year 11 months old. It seemed that lower
residual enzyme activities were associated with an earlier
onset. However, in India report, patient 9 with undetect-
able ARSA activity had disease onset at 2 years 3 months
old. Our limitation was that the case numbers were too
small to draw a definitive conclusion.






















1 1 yr 3mo 11.30 (>71.1) 15.89 Not used Not used p.A316D a/p.W320X
2 1 yr 2mo 11.81 (>71.1) 16.61 Not used Not used p.F249S/c.1344_1345 dupC
p.N352S b
3 1 yr 3mo 11.29 (>71.1) 15.88 Not used Not used p.Q176X a /p.R293X a
4 1 yr 2mo 15.23 (>71.1) 21.42 Not used Not used p.G101V/c.749 insGCGGGCCA a
5 1 yr 11mo 21.86 (>71.1) 30.75 Not used Not used p.G101V/p.G303R a
India
6 [13] 1 yr 6mo 1.23 (>50) 2.46 Not used c.459 + 1G > A/not found c.465 + 1G > A/not found
7 [13] 2 yr 4mo 2.43 (>50) 4.86 Not used p.Y33S/not found p.Y35S/not found
8 [13] 1 yr 6mo 2.45 (>50) 4.90 Not used p.R311Q/ p.R311Q p.R313Q/ p.R313Q
9 [13] 2 yr 3mo Undetectable (>50) NA Not used c.459 + 1G > A/ c.459 +
1G > A
c.465 + 1G > A/ c.465 + 1G > A
10 [13] 1 yr 6mo 0.83 (>50) 1.66 Not used c.752_753insT/not found
c.1524 + 95A > G b
c.758_759insT/not found
c.1530 + 95A > G b
11 [13] 2 yr 6mo 1.40 (>50) 2.80 Not used p.R390W/ p.R390W p.R392W/ p.R392W
12 [13] 2 yr 5.00 (>50) 10.0 Not used p.G245R/ p.G245R p.G247R/ p.G247R
Japan
13 [14] NA NA NA Unknown Unknown p.Q155H/ p.G310V
14 [15] NA NA NA Unknown Unknown p.L300S/ c.225 + 2A > G
15 [16] 1 yr 11mo 15.80 (109.0-217.2) 14.50 Not used Not used p.P138T/ p.P138T
China
16 [17] 1 yr 5mo 7.00 (38.9-98.3) 17.99 p.W318X/ p.W318X Not used p.W320X/ p.W320X
17 [18] 1 yr 7mo 1.19 (NA) NA Not used Not used c.622delC/ c.622delC
Korea
18 [19] 1 yr 4.92 (30–90) 16.40 Unknown Unknown p.G101V/c.1107 + 1G > T
ARSA arylsulfatase A, mo months, NA not available, Ref reference, yr years
aNovel ARSA gene mutations,bARSA pseudodeficiency allele
(See figure on previous page.)
Fig. 1 Cranial MRIs of our patients. a-c represents patient 1, d-f patient 2, g-i patient 3, j-l patient 4, andm-o patient 5. (a, d, g, j, m) Hypointense radially
oriented stripes and dots seen within the hyperintense cerebral white matter (resembling tiger skin) on T2-weighted axial imaging. (b, e, h, k, n)
Hypointense dots resembling leopard skin seen on T2-weighted axial imaging at the level of centrum ovale. (c, f, i, l, o) Iso to hyperintense dots seen in
the cerebral white matter on T1-weighted imaging. This pattern of dysmyelination resembles the skin of tiger (radial stripes) and leopard (dots), the
so-called tigroid and leopard pattern of dysmyelination in metachromatic leukodystrophy
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In Asian countries, the number of reported cases with
late infantile MLD is limited [13–19]. However, a great di-
versity of 22 different alleles of ARSA gene mutations was
found (Table 2). Five novel mutations of ARSA gene were
identified in our patients, including p.A316D, p.G303R,
p.Q176X, p.R293X, and c.749 insGCGGGCCA. As the
frequency of ARSA mutation alleles in normal alleles and
pseudodeficiency alleles was equivalent [33, 34], it is pos-
sible that patients with late infantile MLD carry both
disease-causing and pseudodeficiency alleles. Mutations
whose effects might be exaggerated by the reduced syn-
thesis of ARSA due to pseudodeficiency alleles are likely
to be seen in late infantile MLD patients carrying both of
them [33]. One of our 5 patients, patient 2, carried the
ARSA gene mutations p.F249S and c.1344_1345 dupC
and the ARSA pseudodeficiency allele p.N352S.
Conclusions
In conclusion, patients with late infantile MLD exhibit a
rapid and devastating clinical course. The initial neuro-
logical feature is gait disturbance followed by bed-ridden
status within a couple of months to 2 years. Tigroid and
leopard skin pattern of dysmyelination on brain MRI to-
gether with peripheral demyelination polyneuropathy
serve as a clue indicating that evaluation of ARSA activ-






















p.G101V c.749 insGCGGGCCA 
GGC
GTC
Fig. 2 ARSA gene mutations of our patients. a Patient 1 has ARSA mutations of p.A316D and p.W320X. b Patient 2 has ARSA mutations of
p.F249S, c.1344_1345 dupC, and an additional pseudodeficiency allele of p.N352S. c Patient 3 has ARSA mutations of p.Q176X and p.R293X.
d Patient 4 has ARSA mutations of p.G101V and c.749 insGCGGGCCA. e Patient 5 has ARSA mutations of p.G101V and p.G303R
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mutations could be found in patients with late infantile
MLD in Asia, including p.W320X which was found in
Taiwan and China, and p.G101V in Taiwan and Korea.
An accurate diagnosis of late infantile MLD should be
based on a combination of clinical features, biochemical
analysis of low residual enzyme activity of ARSA in leu-
kocytes, and pathognomonic ARSA gene mutations, in
order to facilitate genetic counseling of family members
and prenatal diagnosis.
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